{
  "meta": {
    "title": "28_Hypoglycemic_Drugs",
    "url": "https://brainandscalpel.vercel.app/28-hypoglycemic-drugs-3b9ad2f8.html",
    "scrapedAt": "2025-11-30T06:59:50.265Z"
  },
  "questions": [
    {
      "id": 59882,
      "choices": [
        {
          "id": 254568,
          "text": "Lactic acidosis"
        },
        {
          "id": 254569,
          "text": "Hypoglycemia"
        },
        {
          "id": 254570,
          "text": "Disulfiram like reaction"
        },
        {
          "id": 254571,
          "text": "Severe hepatic toxicity"
        }
      ],
      "text": "A 54-year-old obese patient with type 2 diabetes mellitus and a history of alcohol is in probably should not receive metformin because it can increase the risk of",
      "unique_key": "Q6164110",
      "question_audio": null,
      "question_video": null,
      "map_id": 34362207,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Lactic acidosis. Metformin, a first-line drug for type 2 diabetes mellitus (T2DM), works by reducing hepatic gluconeogenesis and increasing insulin sensitivity. However, it can lead to lactic acidosis, especially in patients with conditions that predispose them to hypoxia or impaired lactate clearance. Alcoholism, hepatic dysfunction, renal impairment, and hypoxia can all increase the risk of lactic acidosis. Alcohol consumption impairs gluconeogenesis, leading to an accumulation of lactate. When combined with metformin, this risk is significantly elevated. Lactic acidosis presents with symptoms like nausea, vomiting, deep labored breathing (Kussmaul respiration), and altered mental status. Since metformin is renally excreted, any impairment in kidney function (which is common in chronic alcoholics and diabetics) further increases metformin accumulation, worsening the risk of lactic acidosis. Thus, in an obese, alcoholic patient with T2DM, metformin should be avoided due to the high risk of lactic acidosis. Incorrect Options: B. Hypoglycemia: Metformin does not cause hypoglycemia because it does not increase insulin secretion. Unlike sulfonylureas (e.g., glipizide, glyburide) or insulin therapy, metformin mainly reduces glucose production in the liver and enhances insulin sensitivity rather than directly lowering blood glucose levels. Hypoglycemia is not a common side effect of metformin. C. Disulfiram-like reaction: A disulfiram-like reaction (flushing, nausea, vomiting, tachycardia) occurs when alcohol interacts with drugs like metronidazole, certain cephalosporins, and disulfiram itself. Metformin does not inhibit aldehyde dehydrogenase and does not cause a disulfiram-like reaction. D. Severe hepatic toxicity: Metformin is not directly hepatotoxic. However, in patients with severe liver disease, it can contribute to lactic acidosis due to impaired lactate clearance. Unlike drugs like acetaminophen or isoniazid, metformin does not cause direct hepatic toxicity.",
      "correct_choice_id": 254568,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67441071700145266/67441071700145266.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67441071700145266/67441071700145266.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59883,
      "choices": [
        {
          "id": 254572,
          "text": "Tolbutamide"
        },
        {
          "id": 254573,
          "text": "NPH insulin"
        },
        {
          "id": 254574,
          "text": "Crystalline zinc insulin"
        },
        {
          "id": 254575,
          "text": "Ultra Lente insulin"
        }
      ],
      "text": "A 15-year-old girl with type l diabetes is brought to emergency complaining of dizziness. Laboratory findings include severe hyperglycemia, ketoacidosis and blood pH of 7. 15. To achieve rapid control of severe ketoacidosis, appropriate drug is",
      "unique_key": "Q7392748",
      "question_audio": null,
      "question_video": null,
      "map_id": 34358655,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Crystalline zinc insulin (also known as regular insulin). Diabetic ketoacidosis (DKA) is a life-threatening condition characterized by severe hyperglycemia, ketoacidosis, and metabolic acidosis (low blood pH). The mainstay of treatment for DKA is rapid-acting insulin to lower blood glucose and suppress ketogenesis. Crystalline zinc insulin (Regular insulin) is the preferred insulin for DKA because: It is short-acting and can be given intravenously (IV) for immediate effect. It reduces blood glucose levels quickly, halts ketone production, and corrects metabolic acidosis. IV infusion of regular insulin allows precise control over glucose levels and prevents rapid shifts in serum osmolality that could lead to cerebral edema. Subcutaneous insulin is not used initially in DKA because it has delayed onset and unreliable absorption in severely dehydrated patients. Thus, regular insulin (Crystalline zinc insulin) administered IV is the standard treatment for severe DKA. Incorrect Options: A. Tolbutamide: Tolbutamide is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells. It is ineffective in type 1 diabetes because type 1 diabetics have absolute insulin deficiency due to autoimmune destruction of beta cells. It also acts too slowly to be useful in an emergency setting like DKA. B. NPH insulin (Neutral Protamine Hagedorn insulin): NPH insulin is an intermediate-acting insulin with onset in 1-2 hours and peak effect at 4-6 hours. It is too slow-acting to be useful for the rapid correction of ketoacidosis. In DKA, immediate glucose reduction is required, which NPH insulin cannot provide efficiently. D. Ultra Lente insulin: Ultra Lente insulin is a long-acting insulin with an onset of action in 6-8 hours and peak effect at 10-16 hours. It is completely unsuitable for DKA because of its slow onset and prolonged action, making it ineffective for immediate blood glucose control.",
      "correct_choice_id": 254574,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/30496961700145299/30496961700145299.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/30496961700145299/30496961700145299.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59884,
      "choices": [
        {
          "id": 254576,
          "text": "Acarbose"
        },
        {
          "id": 254577,
          "text": "Rosiglitazone"
        },
        {
          "id": 254578,
          "text": "Metformin"
        },
        {
          "id": 254579,
          "text": "Glipizide"
        }
      ],
      "text": "Which of the following drugs is most likely to cause hypoglycemia when used as a monotherapy in the treatment of type 2 diabetes?",
      "unique_key": "Q9794681",
      "question_audio": null,
      "question_video": null,
      "map_id": 34182811,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Glipizide. Glipizide is a second-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells, increasing the risk of hypoglycemia. Sulfonylureas like glipizide, glyburide, and glimepiride act by binding to ATP-sensitive potassium (K-ATP) channels in pancreatic beta cells, leading to increased insulin secretion, regardless of blood glucose levels. Since insulin secretion is not glucose-dependent, excessive insulin release can lead to hypoglycemia, especially in elderly patients, those with renal impairment, or if meals are skipped. Glipizide has a shorter half-life compared to glyburide, making it slightly safer, but it still carries a significant risk of hypoglycemia. Thus, Glipizide is the most likely to cause hypoglycemia among the given options. Incorrect Options: A. Acarbose: Acarbose is an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine. It reduces postprandial glucose spikes but does not directly stimulate insulin secretion, making hypoglycemia rare. When used alone, acarbose does not cause hypoglycemia because it only modulates glucose absorption without increasing insulin levels. B. Rosiglitazone: Rosiglitazone is a thiazolidinedione (TZD) that increases insulin sensitivity in peripheral tissues (muscle, liver, and adipose tissue). It does not stimulate insulin secretion and therefore does not cause hypoglycemia when used as monotherapy. TZDs work by activating PPAR-? receptors, improving glucose uptake without inducing excess insulin release. C. Metformin: Metformin is a biguanide that decreases hepatic glucose production and increases insulin sensitivity. It does not stimulate insulin secretion and does not cause hypoglycemia when used alone. Hypoglycemia with metformin is extremely rare unless combined with other glucose-lowering agents (e.g., sulfonylureas or insulin).",
      "correct_choice_id": 254579,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5011881700145322/5011881700145322.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5011881700145322/5011881700145322.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59885,
      "choices": [
        {
          "id": 254580,
          "text": "They are used first in most cases of uncomplicated mild to moderate type 2 diabetes"
        },
        {
          "id": 254581,
          "text": "They should be prescribed only if the patient refuse insulin injections"
        },
        {
          "id": 254582,
          "text": "They are used in type 1 diabetes mellitus"
        },
        {
          "id": 254583,
          "text": "They are the first choice drug in all cases"
        }
      ],
      "text": "The correct statement regarding the present status of oral hypoglycemic in diabetes mellitus is",
      "unique_key": "Q5456153",
      "question_audio": null,
      "question_video": null,
      "map_id": 34372154,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) They are used first in most cases of uncomplicated mild to moderate type 2 diabetes. Oral hypoglycemic agents (OHAs) are the first-line treatment for most patients with mild to moderate type 2 diabetes mellitus (T2DM), especially when lifestyle modifications alone are insufficient. Metformin is the preferred first-line drug due to its efficacy, weight neutrality, and low risk of hypoglycemia. Other oral drugs, such as sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and thiazolidinediones (TZDs), are added based on patient needs. Insulin therapy is usually reserved for severe cases, failure of oral medications, or specific conditions like pregnancy, severe hyperglycemia, or ketosis-prone diabetes. Thus, oral hypoglycemics are the first choice for most cases of mild to moderate type 2 diabetes, making option A correct. Incorrect Options: B. They should be prescribed only if the patient refuses insulin injections – Incorrect Oral hypoglycemics are not merely an alternative for patients who refuse insulin; they are actually the preferred first-line treatment for type 2 diabetes in most cases. Insulin is generally reserved for patients with severe diabetes, high blood glucose levels, or treatment failure with oral agents. C. They are used in type 1 diabetes mellitus – Incorrect Type 1 diabetes is caused by absolute insulin deficiency due to autoimmune destruction of pancreatic beta cells. Oral hypoglycemics do not work in type 1 diabetes, as they require some residual insulin production. Only insulin therapy is effective for type 1 diabetes. D. They are the first choice drug in all cases – Incorrect While oral hypoglycemics are first-line for most cases of type 2 diabetes, they are not suitable for type 1 diabetes, gestational diabetes, or severe cases requiring insulin therapy. In pregnant women, insulin is preferred over OHAs to prevent fetal complications.",
      "correct_choice_id": 254580,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20719161700145347/20719161700145347.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20719161700145347/20719161700145347.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59886,
      "choices": [
        {
          "id": 254584,
          "text": "It is a long acting oral hypoglycemic drug"
        },
        {
          "id": 254585,
          "text": "It acts by opening K • channels in myocytes and adipocytes"
        },
        {
          "id": 254586,
          "text": "It lowers blood glucose in both type 1 and type 2 diabetes mellitus"
        },
        {
          "id": 254587,
          "text": "Taken just before a meal, it limits post prandial hyperglycemia in type 2 diabetes mellitus"
        }
      ],
      "text": "Which of the Following statements about Nateglinide is TRUE?",
      "unique_key": "Q6937431",
      "question_audio": null,
      "question_video": null,
      "map_id": 34405962,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Taken just before a meal, it limits postprandial hyperglycemia in type 2 diabetes mellitus. Nateglinide is a short-acting meglitinide analog that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium (K + + ) channels. It is taken just before meals to stimulate rapid insulin secretion, thereby reducing postprandial hyperglycemia in type 2 diabetes mellitus (T2DM). Due to its rapid onset and short duration of action, it primarily targets mealtime glucose spikes rather than fasting blood glucose levels. It has a lower risk of prolonged hypoglycemia compared to sulfonylureas due to its short half-life. Thus, Nateglinide is effective in controlling postprandial glucose levels, making option D the correct answer. Incorrect Options: A. It is a long-acting oral hypoglycemic drug – Incorrect Nateglinide is a short-acting insulin secretagogue with a rapid onset and short half-life (~1 hour). It is not used for basal glucose control and must be taken before each meal for postprandial glucose regulation. Long-acting agents like metformin, sulfonylureas, and thiazolidinediones (TZDs) are used for maintaining baseline glucose levels. B. It acts by opening K + + channels in myocytes and adipocytes – Incorrect Nateglinide actually closes ATP-sensitive K + + channels in pancreatic beta cells, leading to depolarization, calcium influx, and insulin release. It does not act on myocytes (muscle cells) or adipocytes (fat cells). C. It lowers blood glucose in both type 1 and type 2 diabetes mellitus – Incorrect Nateglinide requires functional beta cells to stimulate insulin secretion, meaning it is ineffective in type 1 diabetes mellitus (T1DM), where beta cells are destroyed. It is only used in type 2 diabetes mellitus, where some beta-cell function remains.",
      "correct_choice_id": 254587,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13859571700145365/13859571700145365.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13859571700145365/13859571700145365.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59887,
      "choices": [
        {
          "id": 254588,
          "text": "Type 2 Diabetics"
        },
        {
          "id": 254589,
          "text": "Obese diabetic"
        },
        {
          "id": 254590,
          "text": "Non diabetics"
        },
        {
          "id": 254591,
          "text": "Diabetics not responding to sulfonylureas"
        }
      ],
      "text": "Metformin is NOT effective in lowering of blood sugar level in which of the following patients?",
      "unique_key": "Q4339699",
      "question_audio": null,
      "question_video": null,
      "map_id": 34694335,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Non-diabetics. Metformin is not effective in lowering blood sugar levels in non-diabetic individuals because its glucose-lowering effect depends on the presence of hyperglycemia. Metformin works by decreasing hepatic gluconeogenesis (glucose production by the liver) and improving insulin sensitivity in peripheral tissues (muscles and adipose tissue). In non-diabetics, blood glucose levels are already regulated by normal insulin function, and since metformin does not stimulate insulin secretion, it does not lower glucose levels in those with normal glucose metabolism. Additionally, it does not cause hypoglycemia in non-diabetics, unlike insulin or sulfonylureas, which can force glucose levels to drop even when they are normal. Thus, metformin has no significant glucose-lowering effect in non-diabetics, making option C the correct answer. Incorrect Options: A. Type 2 Diabetics – Incorrect Metformin is the first-line drug for type 2 diabetes mellitus (T2DM). It reduces blood glucose levels by improving insulin sensitivity and decreasing hepatic glucose output. It is highly effective in lowering blood sugar in type 2 diabetics, especially those with insulin resistance. B. Obese Diabetic – Incorrect Metformin is particularly beneficial in obese diabetics because it does not cause weight gain, unlike insulin or sulfonylureas. It also helps with weight loss by reducing appetite and improving metabolism. Thus, it is an effective and preferred choice for overweight or obese type 2 diabetics. D. Diabetics not responding to sulfonylureas – Incorrect Metformin can be effective in patients who do not respond to sulfonylureas (e.g., due to insulin resistance). Sulfonylureas work by stimulating insulin secretion from the pancreas, but if insulin resistance is the main problem, metformin can help improve glucose control by increasing insulin sensitivity. It is often used in combination with sulfonylureas for better glycemic control.",
      "correct_choice_id": 254590,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76098881700145381/76098881700145381.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76098881700145381/76098881700145381.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59888,
      "choices": [
        {
          "id": 254592,
          "text": "Non diabetics"
        },
        {
          "id": 254593,
          "text": "Obese diabetics"
        },
        {
          "id": 254594,
          "text": "Type 2 diabetics"
        },
        {
          "id": 254595,
          "text": "Type 1 diabetics"
        }
      ],
      "text": "Glibenclamide reduces blood glucose in all of the following EXCEPT",
      "unique_key": "Q9841878",
      "question_audio": null,
      "question_video": null,
      "map_id": 34189231,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Type 1 diabetics. Glibenclamide (also called glyburide) is a sulfonylurea that lowers blood glucose by stimulating insulin secretion from pancreatic beta cells. Type 1 diabetes mellitus (T1DM) is characterized by the complete destruction or absence of functional beta cells in the pancreas. Since sulfonylureas require functional beta cells to exert their effect, they are ineffective in type 1 diabetics. In type 1 diabetes, insulin therapy is required because the pancreas is unable to produce insulin. Even if glibenclamide is given, it will not lower blood sugar in type 1 diabetics because there are no beta cells to stimulate. Thus, glibenclamide does not work in type 1 diabetes, making option D the correct answer. Incorrect Options: A. Non-diabetics – Incorrect Glibenclamide stimulates insulin release regardless of blood glucose levels. In non-diabetics, where insulin secretion is already properly regulated, additional stimulation by glibenclamide can cause an excessive drop in blood sugar, leading to hypoglycemia. This is why sulfonylureas should not be given to non-diabetics. B. Obese diabetics – Incorrect Glibenclamide is effective in obese type 2 diabetics as long as they still have functional beta cells. However, it is not the preferred drug in obese diabetics because sulfonylureas can cause weight gain. Metformin is preferred in obese diabetics because it improves insulin sensitivity without causing weight gain. C. Type 2 diabetics – Incorrect Glibenclamide is primarily used for type 2 diabetes mellitus (T2DM). Type 2 diabetics still have functional beta cells, although they may have reduced insulin secretion or insulin resistance. Glibenclamide helps by stimulating insulin release, making it an effective treatment for type 2 diabetes.",
      "correct_choice_id": 254595,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58004101700145397/58004101700145397.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58004101700145397/58004101700145397.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59889,
      "choices": [
        {
          "id": 254596,
          "text": "It is more potent"
        },
        {
          "id": 254597,
          "text": "It does not interfere with vitamin B, 2 absorption"
        },
        {
          "id": 254598,
          "text": "It is less liable to cause lactic acidosis"
        },
        {
          "id": 254599,
          "text": "It is not contraindicated in patients with kidney disease"
        }
      ],
      "text": "Which of the following characteristics make metformin a preferred biguanide than phenformin?",
      "unique_key": "Q4740877",
      "question_audio": null,
      "question_video": null,
      "map_id": 34946559,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) It is less liable to cause lactic acidosis. Metformin is a biguanide that is widely used for the treatment of type 2 diabetes mellitus (T2DM). It is preferred over phenformin, another biguanide, because it has a significantly lower risk of lactic acidosis. Phenformin was withdrawn from the market in many countries due to its strong association with lactic acidosis, a life-threatening condition that occurs due to excessive accumulation of lactic acid in the blood. Metformin has a much lower risk of causing lactic acidosis because it is cleared more efficiently by the kidneys and has a weaker effect on inhibiting hepatic gluconeogenesis. Metformin remains the first-line drug for type 2 diabetes because of its better safety profile, effectiveness, and reduced risk of lactic acidosis compared to phenformin. Thus, option C is correct because metformin is preferred over phenformin due to its lower risk of causing lactic acidosis. Incorrect Options: A. It is more potent – Incorrect Metformin is actually less potent than phenformin. Phenformin was more powerful in reducing blood glucose but had an unacceptably high risk of lactic acidosis. Safety, not potency, is the main reason metformin is preferred. B. It does not interfere with vitamin B12 absorption – Incorrect Metformin is known to interfere with vitamin B12 absorption and can cause vitamin B12 deficiency in long-term use. This deficiency can lead to neuropathy and anemia. Therefore, this is not a reason for preferring metformin over phenformin. D. It is not contraindicated in patients with kidney disease – Incorrect Metformin is contraindicated in kidney disease because it is renally excreted. If kidney function is impaired, metformin can accumulate in the blood and increase the risk of lactic acidosis. Thus, metformin is not safe for patients with renal failure, making this statement incorrect.",
      "correct_choice_id": 254598,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21191031700145411/21191031700145411.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21191031700145411/21191031700145411.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59890,
      "choices": [
        {
          "id": 254600,
          "text": "Enzymatic receptor"
        },
        {
          "id": 254601,
          "text": "Ionotropic receptor"
        },
        {
          "id": 254602,
          "text": "Metabotropic receptor"
        },
        {
          "id": 254603,
          "text": "Nuclear receptor"
        }
      ],
      "text": "Insulin acts by stimulation of",
      "unique_key": "Q5836013",
      "question_audio": null,
      "question_video": null,
      "map_id": 34519810,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Enzymatic receptor. Insulin acts by stimulating an enzymatic receptor, specifically the insulin receptor, which is a tyrosine kinase receptor. This receptor plays a crucial role in glucose metabolism and cellular growth. The insulin receptor is a transmembrane receptor with intrinsic tyrosine kinase activity. When insulin binds to its receptor, it triggers autophosphorylation of tyrosine residues on the intracellular domain of the receptor. This phosphorylation event activates a cascade of intracellular signaling pathways, including the PI3K-Akt and MAPK pathways, leading to glucose uptake, glycogen synthesis, and other metabolic effects. Thus, insulin acts via an enzymatic receptor, making option A correct. Incorrect Options: B. Ionotropic receptor – Incorrect Ionotropic receptors are ligand-gated ion channels that mediate fast synaptic transmission by directly altering ion flow across the membrane. Examples include nicotinic acetylcholine receptors, GABA-A receptors, and NMDA receptors. Insulin does not act through ion channels, so this option is incorrect. C. Metabotropic receptor – Incorrect Metabotropic receptors are G-protein-coupled receptors (GPCRs) that mediate cellular responses through secondary messengers (e.g., cAMP, IP3). Examples include muscarinic acetylcholine receptors and adrenergic receptors. Insulin does not act through GPCRs, but instead through a tyrosine kinase receptor, making this option incorrect. D. Nuclear receptor – Incorrect Nuclear receptors are intracellular receptors that regulate gene expression by binding to DNA. Examples include glucocorticoid receptors, estrogen receptors, and thyroid hormone receptors. Insulin does not act via nuclear receptors, so this option is incorrect.",
      "correct_choice_id": 254600,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4379861700145425/4379861700145425.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4379861700145425/4379861700145425.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59891,
      "choices": [
        {
          "id": 254604,
          "text": "An old man with severe bradycardia and hypotension resulting from ingestion of overdose of atenolol"
        },
        {
          "id": 254605,
          "text": "A middle aged man with type II diabetes who has not taken his regular dose of glipizide for last 4 days"
        },
        {
          "id": 254606,
          "text": "A young man who took cocaine and has a blood pressure of 190/110 mm Hg"
        },
        {
          "id": 254607,
          "text": "An old woman with lactic acidosis as a complication of severe infection and shock"
        }
      ],
      "text": "Which of the following patients is most likely to be treated with intravenous glucagon?",
      "unique_key": "Q4562208",
      "question_audio": null,
      "question_video": null,
      "map_id": 34093531,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) An old man with severe bradycardia and hypotension resulting from ingestion of an overdose of atenolol. Glucagon is an effective treatment for β-blocker overdose, including atenolol. β-blockers (such as atenolol) inhibit β-adrenergic receptors, reducing heart rate and blood pressure, leading to severe bradycardia and hypotension. Glucagon bypasses β-receptor blockade by directly activating adenylate cyclase in cardiac myocytes, increasing cAMP and leading to improved cardiac contractility and heart rate. It is the drug of choice for severe β-blocker toxicity when standard treatments such as atropine and intravenous fluids fail. Thus, intravenous glucagon is the most appropriate treatment for this patient. Incorrect Options: B. A middle-aged man with type II diabetes who has not taken his regular dose of glipizide for the last 4 days – Incorrect Glucagon is used to treat hypoglycemia, not hyperglycemia. This patient has not taken glipizide (a sulfonylurea that stimulates insulin release) for 4 days, meaning his blood glucose is likely to be high, not low. He does not need glucagon therapy. C. A young man who took cocaine and has a blood pressure of 190/110 mm Hg – Incorrect Cocaine causes severe hypertension and tachycardia by increasing sympathetic activity (excess norepinephrine and dopamine). Glucagon does not reduce blood pressure or treat cocaine toxicity. The preferred treatment for cocaine-induced hypertension is benzodiazepines (e.g., diazepam or lorazepam) and calcium channel blockers, not glucagon. D. An old woman with lactic acidosis as a complication of severe infection and shock – Incorrect Lactic acidosis results from impaired tissue oxygenation and anaerobic metabolism due to sepsis or shock. Glucagon does not correct lactic acidosis; instead, treatment involves fluid resuscitation, oxygen therapy, and correcting the underlying cause (such as infection).",
      "correct_choice_id": 254604,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7945881700145439/7945881700145439.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7945881700145439/7945881700145439.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59892,
      "choices": [
        {
          "id": 254608,
          "text": "Nateglinide"
        },
        {
          "id": 254609,
          "text": "Glipizide"
        },
        {
          "id": 254610,
          "text": "Acarbose"
        },
        {
          "id": 254611,
          "text": "Pioglitazone"
        }
      ],
      "text": "Which of the following drugs is taken during the first part of the meal for the purpose of delaying absorption of dietary carbohydrates?",
      "unique_key": "Q3648221",
      "question_audio": null,
      "question_video": null,
      "map_id": 34249840,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Acarbose. Acarbose is an α-glucosidase inhibitor that delays carbohydrate absorption in the intestine. It acts by inhibiting the α-glucosidase enzyme in the brush border of the small intestine, which is responsible for breaking down complex carbohydrates into glucose. This delay in carbohydrate digestion slows glucose absorption and helps in controlling postprandial blood sugar spikes. It should be taken at the start of a meal so that it can effectively inhibit carbohydrate breakdown and absorption. It is particularly useful for patients with type 2 diabetes to control postprandial hyperglycemia. Thus, Acarbose is the most appropriate drug for delaying the absorption of dietary carbohydrates. Incorrect Options: A. Nateglinide – Incorrect Nateglinide is a rapid-acting insulin secretagogue (meglitinide class) that stimulates insulin release from pancreatic β-cells. It is taken before meals to prevent postprandial hyperglycemia, but it does not delay carbohydrate absorption. B. Glipizide – Incorrect Glipizide is a sulfonylurea that increases insulin secretion from the pancreas. It helps in lowering blood glucose but does not affect carbohydrate digestion or absorption. D. Pioglitazone – Incorrect Pioglitazone is a thiazolidinedione (TZD) that improves insulin sensitivity in muscle and fat cells. It has no effect on the absorption of carbohydrates and works by increasing glucose uptake rather than delaying its absorption.",
      "correct_choice_id": 254610,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24108461700145454/24108461700145454.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24108461700145454/24108461700145454.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59893,
      "choices": [
        {
          "id": 254612,
          "text": "Glimepiride"
        },
        {
          "id": 254613,
          "text": "Pioglitazone"
        },
        {
          "id": 254614,
          "text": "Sitagliptin"
        },
        {
          "id": 254615,
          "text": "Acarbose"
        }
      ],
      "text": "The oral diabetic dispensed with black box warning of bladder cancer is",
      "unique_key": "Q7867293",
      "question_audio": null,
      "question_video": null,
      "map_id": 34762481,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Pioglitazone. Pioglitazone, a thiazolidinedione (TZD) class drug, is used for treating type 2 diabetes mellitus by increasing insulin sensitivity in peripheral tissues. However, it carries a black box warning due to its association with an increased risk of bladder cancer. Studies have shown that long-term use of pioglitazone may elevate this risk, leading regulatory agencies like the FDA and EMA to issue warnings regarding its use, particularly in patients with a history of bladder cancer. Incorrect Options: (A) Glimepiride – Incorrect Glimepiride is a sulfonylurea that lowers blood glucose by stimulating insulin secretion from pancreatic β-cells. While it carries a risk of hypoglycemia and weight gain, it does not have a black box warning for bladder cancer. (C) Sitagliptin – Incorrect Sitagliptin is a DPP-4 inhibitor that improves glucose control by increasing incretin hormones (GLP-1 and GIP), leading to increased insulin secretion and reduced glucagon release. Its main warnings include pancreatitis and joint pain, but not bladder cancer. (D) Acarbose – Incorrect Acarbose is an α-glucosidase inhibitor that slows carbohydrate digestion and absorption, reducing postprandial hyperglycemia. It primarily causes gastrointestinal side effects (flatulence, diarrhea) but has no association with bladder cancer.",
      "correct_choice_id": 254613,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9444181700145877/9444181700145877.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/9444181700145877/9444181700145877.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59894,
      "choices": [
        {
          "id": 254616,
          "text": "Advanced age"
        },
        {
          "id": 254617,
          "text": "Liver dysfunction"
        },
        {
          "id": 254618,
          "text": "Renal dysfunction"
        },
        {
          "id": 254619,
          "text": "Smoking"
        }
      ],
      "text": "All of the following is supposed to increase the risk of lactic acidosis in a patient taking metformin except",
      "unique_key": "Q3824435",
      "question_audio": null,
      "question_video": null,
      "map_id": 34972265,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Smoking. Smoking does not directly contribute to the risk of lactic acidosis in a patient taking metformin. Metformin-associated lactic acidosis is primarily linked to conditions that impair lactate clearance or increase lactate production, such as renal or hepatic dysfunction. While smoking has many adverse health effects, including increased cardiovascular risks, it does not significantly interfere with metformin metabolism or lactate clearance. Incorrect Options: (A) Advanced Age – Increases Risk Elderly patients (especially >80 years) have reduced renal function even if their serum creatinine appears normal. Since metformin is renally excreted, decreased kidney function can lead to drug accumulation, increasing the risk of lactic acidosis. (B) Liver Dysfunction – Increases Risk The liver plays a crucial role in lactate metabolism. In liver dysfunction (e.g., cirrhosis, severe hepatitis), lactate clearance is impaired, leading to increased blood lactate levels and higher risk of lactic acidosis. This is why metformin is contraindicated in severe liver disease. (C) Renal Dysfunction – Increases Risk Metformin is eliminated through the kidneys, and renal impairment can cause drug accumulation, leading to high plasma levels and an increased risk of lactic acidosis. Chronic kidney disease (CKD) stages 3–5 are especially concerning, and metformin is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73m²).",
      "correct_choice_id": 254619,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41461701700145897/41461701700145897.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41461701700145897/41461701700145897.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59895,
      "choices": [
        {
          "id": 254620,
          "text": "Glucagon"
        },
        {
          "id": 254621,
          "text": "Hydrocortisone"
        },
        {
          "id": 254622,
          "text": "Octreotide"
        },
        {
          "id": 254623,
          "text": "Adrenaline"
        }
      ],
      "text": "A specific antidote for sulfonylurea-induced hypoglycemia",
      "unique_key": "Q9547521",
      "question_audio": null,
      "question_video": null,
      "map_id": 34019114,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Octreotide. Octreotide is the specific antidote for sulfonylurea-induced hypoglycemia. Sulfonylureas (e.g., glipizide, glyburide) stimulate insulin release from pancreatic beta cells by blocking ATP-sensitive potassium (K + + ) channels. This excessive insulin release leads to persistent hypoglycemia, which may not always respond to dextrose alone. Octreotide is a somatostatin analog that inhibits insulin secretion by blocking calcium influx into pancreatic beta cells. This prevents further endogenous insulin release, making it the preferred treatment for persistent sulfonylurea-induced hypoglycemia. Incorrect Options: (A) Glucagon – Incorrect Glucagon stimulates glycogenolysis and gluconeogenesis, raising blood glucose levels. However, in sulfonylurea-induced hypoglycemia, glucagon is often ineffective because excessive insulin secretion quickly counteracts its effects. Additionally, glucagon may worsen hypoglycemia later by depleting glycogen stores, making it an unreliable treatment in this scenario. (B) Hydrocortisone – Incorrect Hydrocortisone is a glucocorticoid that increases blood glucose by stimulating gluconeogenesis. However, its effects are too slow for the acute management of sulfonylurea-induced hypoglycemia. (D) Adrenaline – Incorrect Adrenaline (epinephrine) promotes glycogenolysis and inhibits insulin release, but it is not the preferred treatment for sulfonylurea-induced hypoglycemia. It may also have significant cardiovascular side effects, such as tachycardia and hypertension, making it less suitable than octreotide.",
      "correct_choice_id": 254622,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78364611700145945/78364611700145945.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78364611700145945/78364611700145945.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59896,
      "choices": [
        {
          "id": 254624,
          "text": "Hypernatremia"
        },
        {
          "id": 254625,
          "text": "Hypokalemia"
        },
        {
          "id": 254626,
          "text": "Hypocalcaemia"
        },
        {
          "id": 254627,
          "text": "Hyperuricaemia"
        }
      ],
      "text": "A patient was diagnosed with diabetic ketoacidosis, but the treating intern gave only insulin rapidly to lower blood glucose. What complication is expected by this",
      "unique_key": "Q1246293",
      "question_audio": null,
      "question_video": null,
      "map_id": 34251371,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Hypokalemia. Hypokalemia is a major complication of rapid insulin administration in diabetic ketoacidosis (DKA). In DKA, there is a total body potassium deficit despite normal or elevated serum potassium levels at presentation. This occurs because insulin deficiency and acidosis cause potassium to shift out of cells into the bloodstream. When insulin is administered, it drives potassium back into cells, leading to a sudden drop in serum potassium levels and potentially severe hypokalemia. Severe hypokalemia can result in muscle weakness, cardiac arrhythmias, and even respiratory failure. This is why potassium supplementation is essential in the management of DKA, even before insulin therapy in cases where initial potassium levels are low. Incorrect Options: (A) Hypernatremia – Incorrect In DKA, sodium levels may appear low due to hyperglycemia-induced osmotic shifts (pseudo-hyponatremia). Rapid correction of hyperglycemia with insulin usually leads to a decrease in serum osmolality, but does not cause hypernatremia. (C) Hypocalcemia – Incorrect Insulin therapy does not directly affect calcium levels. While calcium levels can fluctuate due to acid-base changes, clinically significant hypocalcemia is not a major concern in DKA treatment. (D) Hyperuricemia – Incorrect DKA can be associated with hyperuricemia due to dehydration and increased purine metabolism, but insulin therapy itself does not cause significant hyperuricemia.",
      "correct_choice_id": 254625,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/39735281700145998/39735281700145998.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/39735281700145998/39735281700145998.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59897,
      "choices": [
        {
          "id": 254628,
          "text": "Affinity"
        },
        {
          "id": 254629,
          "text": "Duration of Action"
        },
        {
          "id": 254630,
          "text": "Efficacy"
        },
        {
          "id": 254631,
          "text": "Rapid Onset"
        }
      ],
      "text": "A small amount of Zinc is added in insulin preparations to improve",
      "unique_key": "Q6042989",
      "question_audio": null,
      "question_video": null,
      "map_id": 34959055,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Duration of Action. Zinc is added to insulin preparations to prolong its duration of action. Zinc helps in stabilizing insulin hexamers, which delays their dissociation into monomers—the form that can be absorbed and utilized by the body. This slows the absorption of insulin from the injection site, leading to a longer duration of action. For example, intermediate-acting insulins like NPH (Neutral Protamine Hagedorn) insulin and long-acting insulins like Ultralente insulin contain zinc to modulate their release and extend their action time. Incorrect Options: (A) Affinity – Incorrect Zinc does not influence the affinity of insulin for its receptor. The insulin receptor's binding affinity is determined by the insulin molecule itself, not by added zinc. (C) Efficacy – Incorrect Zinc does not directly increase the efficacy of insulin. Efficacy is determined by insulin’s ability to lower blood glucose levels, which is more related to dose, receptor sensitivity, and metabolic state of the patient. (D) Rapid Onset – Incorrect In fact, zinc delays insulin absorption by stabilizing hexamer formation, meaning it does the opposite of increasing rapid onset. Rapid-acting insulins (e.g., Lispro, Aspart, Glulisine) are modified to prevent hexamer formation, allowing faster absorption.",
      "correct_choice_id": 254629,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40576071700146045/40576071700146045.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40576071700146045/40576071700146045.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59898,
      "choices": [
        {
          "id": 254632,
          "text": "Sitagliptin"
        },
        {
          "id": 254633,
          "text": "Linagliptin"
        },
        {
          "id": 254634,
          "text": "Saxagliptin"
        },
        {
          "id": 254635,
          "text": "Alogliptin"
        }
      ],
      "text": "Which of the following drug is approved as FDC with empagliflozin recently",
      "unique_key": "Q1511577",
      "question_audio": null,
      "question_video": null,
      "map_id": 34282714,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Linagliptin. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, commonly used in the management of type 2 diabetes mellitus (T2DM). Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is often combined with SGLT2 inhibitors to enhance glycemic control through complementary mechanisms. The fixed-dose combination (FDC) of empagliflozin and linagliptin has been approved to provide dual benefits—SGLT2 inhibitors reduce renal glucose reabsorption, promoting glucosuria, while DPP-4 inhibitors increase incretin levels, stimulating insulin secretion and reducing glucagon production. This combination offers better glycemic control, potential cardiovascular benefits, and renal protection compared to monotherapy. Explanation of Incorrect Options: (A) Sitagliptin: Sitagliptin is a well-known DPP-4 inhibitor; however, an FDC of empagliflozin and sitagliptin has not been recently approved. Instead, sitagliptin is commonly combined with metformin or used as monotherapy for T2DM. (C) Saxagliptin: While saxagliptin is another DPP-4 inhibitor, it is not the approved FDC with empagliflozin. Instead, saxagliptin has been used in FDCs with metformin (e.g., Kombiglyze XR). (D) Alogliptin: Alogliptin, also a DPP-4 inhibitor, is available in combinations with pioglitazone and metformin but has not been approved as an FDC with empagliflozin.",
      "correct_choice_id": 254633,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6204091700146063/6204091700146063.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6204091700146063/6204091700146063.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59899,
      "choices": [
        {
          "id": 254636,
          "text": "Metformin"
        },
        {
          "id": 254637,
          "text": "Liraglutide"
        },
        {
          "id": 254638,
          "text": "Canagliflozin"
        },
        {
          "id": 254639,
          "text": "Linagliptin"
        }
      ],
      "text": "A 52 year old male, who is obese as well as smoker suffering from DM II and PVD, taking tablet glimepride 2 mg twice daily , comes to hospital OPD with fluctuating blood sugar level. As a physician you add one more anti diabetic drug to above tretament to control sugar level. Even after adding this new drug, patient sugar level keeps on fluctuating and he has to get admitted in hospital for one or two episodes of DKA with UTI. Now this patient comes to hospital emergency with tibial fracture after a trivial fall and while fixing his fracture, surgeon found his lower limb needs to get amputated due to lack of blood supply which can be seen as a sudden complication arisen due to DVT in that particular limb. Which of the following drug might be associated with above complications",
      "unique_key": "Q4459870",
      "question_audio": null,
      "question_video": null,
      "map_id": 34169065,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Canagliflozin Explanation for the Correct Answer: The most likely drug responsible for the complications observed in this patient is Canagliflozin, an SGLT2 inhibitor. SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors) like Canagliflozin work by promoting renal glucose excretion, leading to reduced blood glucose levels. These drugs are known to cause increased risk of diabetic ketoacidosis (DKA), urinary tract infections (UTI), and Fournier’s gangrene, all of which were observed in this patient. A major safety concern with Canagliflozin is its association with an increased risk of lower limb amputations, particularly in patients with peripheral vascular disease (PVD), diabetes, and smoking history. The exact mechanism is unclear, but it is believed to involve volume depletion, increased hematocrit, and impaired wound healing, leading to ischemia and thrombosis. Given that the patient already had PVD, smoking history, and diabetes, he was at high risk for lower limb complications, and Canagliflozin likely exacerbated these risks, resulting in DVT and subsequent amputation. Thus, Canagliflozin (C) is the most likely culprit for the complications in this patient. Explanation for the Incorrect Answers: (A) Metformin Metformin is a first-line treatment for Type 2 Diabetes Mellitus (DM II) and does not cause fluctuations in blood sugar levels. The primary risks associated with Metformin include lactic acidosis in renal failure and gastrointestinal side effects, but it does not increase the risk of DKA, UTIs, or amputations. (B) Liraglutide Liraglutide is a GLP-1 receptor agonist, which helps in glucose-dependent insulin secretion and weight loss. It is not known to cause DKA, UTIs, or amputations but can have side effects like nausea, pancreatitis, and delayed gastric emptying. In fact, GLP-1 receptor agonists are considered cardiovascular protective and are recommended in patients with diabetes and PVD. (D) Linagliptin Linagliptin is a DPP-4 inhibitor, which works by increasing incretin levels to improve insulin secretion. It is not associated with amputations, DKA, or severe infections and is usually well tolerated. It is a safer option in patients with CKD and PVD compared to SGLT2 inhibitors.",
      "correct_choice_id": 254638,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52613131700305922/52613131700305922.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52613131700305922/52613131700305922.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59900,
      "choices": [
        {
          "id": 254640,
          "text": "Sitagliptin"
        },
        {
          "id": 254641,
          "text": "Linagliptin"
        },
        {
          "id": 254642,
          "text": "Vildagliptin"
        },
        {
          "id": 254643,
          "text": "Saxagliptin"
        }
      ],
      "text": "A 60 year old diabetic patient with nephropathy comes to you with high blood sugar which is not getting controlled with treatment he is taking. As a endocrinologist you want to add one more anti diabetic to above treatment . Which of the following anti-diabetic drug is most suitable to be addded in above patient treatment ?",
      "unique_key": "Q9025733",
      "question_audio": null,
      "question_video": null,
      "map_id": 34592124,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Linagliptin Explanation for the Correct Answer: Linagliptin is the best choice for this patient because: Linagliptin is a DPP-4 inhibitor that improves glycemic control by increasing incretin levels, which enhance insulin secretion and reduce glucagon secretion. Unlike most DPP-4 inhibitors, Linagliptin is eliminated primarily via the hepatobiliary route, meaning it does not require dose adjustment in patients with chronic kidney disease (CKD), including diabetic nephropathy. This makes Linagliptin the safest choice for a diabetic patient with nephropathy, as it provides effective glucose control without worsening renal function. Thus, Linagliptin (B) is the most suitable drug in this scenario. Explanation for the Incorrect Answers: (A) Sitagliptin Sitagliptin is also a DPP-4 inhibitor, but it is primarily eliminated via the kidneys. In patients with diabetic nephropathy (CKD), dose adjustment is required, and an improper dose may lead to drug accumulation and increased side effects. Therefore, while it is effective, it is not as safe as Linagliptin for patients with renal impairment. (C) Vildagliptin Vildagliptin is another DPP-4 inhibitor that requires dose adjustment in CKD patients. It has higher risk of hepatotoxicity, and its use is not preferred in patients with moderate to severe renal impairment. Hence, it is not the best option for this patient. (D) Saxagliptin Saxagliptin is primarily excreted renally, and in CKD patients, dose reduction is required to prevent drug accumulation. Additionally, Saxagliptin has been associated with an increased risk of heart failure, making it a less favorable option for patients with diabetic nephropathy.",
      "correct_choice_id": 254641,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49395991700305942/49395991700305942.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49395991700305942/49395991700305942.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59901,
      "choices": [
        {
          "id": 254644,
          "text": "Weight loss"
        },
        {
          "id": 254645,
          "text": "Nausea and vomiting"
        },
        {
          "id": 254646,
          "text": "Hypoglycemia"
        },
        {
          "id": 254647,
          "text": "Pancreatitits"
        }
      ],
      "text": "A 30 year old obese male diagnosed recently with DM II. He also has family history of MI. As a part of his treatment you have started tab metformin plus injection liraglutide, as both of these drug help in prevention of cardiovascular mortality as well as will take care of patient weight. Which of the following cannot be seen as a side effect of above regimen?",
      "unique_key": "Q1730138",
      "question_audio": null,
      "question_video": null,
      "map_id": 34900326,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Hypoglycemia Explanation for the Correct Answer: Hypoglycemia is not a common side effect of the combination of metformin and liraglutide because: Metformin is an insulin sensitizer that decreases hepatic glucose production and improves insulin sensitivity without directly increasing insulin secretion. Liraglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion. This means it only stimulates insulin release when blood glucose levels are elevated, reducing the risk of hypoglycemia. Since neither drug directly lowers blood glucose levels below normal, the risk of hypoglycemia with this regimen is minimal unless combined with insulin or sulfonylureas. Thus, hypoglycemia (C) is not a typical side effect of metformin plus liraglutide therapy. Explanation for the Incorrect Answers: (A) Weight Loss Liraglutide is known for its weight loss benefits due to its effects on appetite suppression and delayed gastric emptying. Metformin may also contribute to modest weight loss by reducing hepatic glucose output and improving insulin sensitivity. Therefore, weight loss is a common and expected effect of this regimen. (B) Nausea and Vomiting Liraglutide frequently causes gastrointestinal side effects, particularly in the initial weeks of therapy. Nausea and vomiting occur due to delayed gastric emptying and activation of GLP-1 receptors in the brain’s vomiting center. These symptoms usually subside over time as the body adapts to the medication. (D) Pancreatitis GLP-1 receptor agonists, including liraglutide, have been associated with an increased risk of pancreatitis. Patients with a history of pancreatitis or gallbladder disease are at higher risk. Symptoms like severe abdominal pain, nausea, and vomiting warrant immediate discontinuation of liraglutide.",
      "correct_choice_id": 254646,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4931251700305956/4931251700305956.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/4931251700305956/4931251700305956.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59902,
      "choices": [
        {
          "id": 254648,
          "text": "Empagliflozin"
        },
        {
          "id": 254649,
          "text": "Linagliptin"
        },
        {
          "id": 254650,
          "text": "Liraglutide"
        },
        {
          "id": 254651,
          "text": "Bromocriptine"
        }
      ],
      "text": "A 52 year male with a history of one episode of MI diagnosed with DM-II. As a diabetologist you want to give antidiabetic to this patient that should also has a role in prevention of cardiovascular mortality. All of the following drug you can prescribe to this patient except:",
      "unique_key": "Q2977251",
      "question_audio": null,
      "question_video": null,
      "map_id": 34261241,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Linagliptin Explanation for the Correct Answer: Linagliptin is a DPP-4 inhibitor, which is effective in lowering blood glucose levels but does not have a significant role in reducing cardiovascular (CV) mortality. Unlike SGLT2 inhibitors (e.g., Empagliflozin) and GLP-1 receptor agonists (e.g., Liraglutide), DPP-4 inhibitors have shown neutral effects on cardiovascular outcomes in major clinical trials. Although DPP-4 inhibitors like linagliptin are safe in patients with diabetes and cardiovascular disease, they do not provide additional cardiovascular protection and are not the preferred choice for patients with a history of MI. Therefore, linagliptin is the least preferred option in this scenario, making it the correct answer. Explanation for the Incorrect Answers: (A) Empagliflozin Empagliflozin is an SGLT2 inhibitor that has been shown to reduce cardiovascular mortality, heart failure hospitalizations, and progression of kidney disease in diabetic patients. The EMPA-REG OUTCOME trial demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and cardiovascular disease. Due to its cardioprotective effects, empagliflozin should be considered in diabetic patients with a history of MI. (C) Liraglutide Liraglutide is a GLP-1 receptor agonist that has been shown to reduce cardiovascular mortality in diabetic patients. The LEADER trial demonstrated that liraglutide significantly reduced MACE, including MI and stroke. Therefore, liraglutide is an excellent choice for a diabetic patient with prior MI. (D) Bromocriptine Bromocriptine is a dopamine agonist that has been approved for the treatment of type 2 diabetes. It has shown some potential benefits in reducing cardiovascular events, possibly due to its effects on insulin sensitivity and autonomic function. While its role in cardiovascular protection is not as strong as SGLT2 inhibitors or GLP-1 receptor agonists, it may still have some cardiovascular benefits.",
      "correct_choice_id": 254649,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49264101700305969/49264101700305969.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49264101700305969/49264101700305969.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59903,
      "choices": [
        {
          "id": 254652,
          "text": "Advanced age"
        },
        {
          "id": 254653,
          "text": "Liver dysfunction"
        },
        {
          "id": 254654,
          "text": "Renal dysfunction"
        },
        {
          "id": 254655,
          "text": "Smoking"
        }
      ],
      "text": "A 45 year old male diabetic patient taking 1000 mg of metformin twice daily for high sugar level and his diesase is well controlled. He is presented to hospital emergency with nausea, vomiting, diarrhea, altered mental status and shortness of breath . Physical examination reveals he has tachycardia, hypotension, tachypnea. His ABG shows severe acidosis but blood sugar level is within range. All of the following can be the risk factors for above complications except",
      "unique_key": "Q3338746",
      "question_audio": null,
      "question_video": null,
      "map_id": 34809609,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Smoking Explanation for the Correct Answer: Smoking is not a known risk factor for metformin-associated lactic acidosis (MALA). While smoking is harmful and contributes to cardiovascular disease and insulin resistance, it does not directly increase the risk of lactic acidosis in a patient taking metformin. Metformin is generally well-tolerated, but in certain conditions that impair lactate clearance, it can lead to severe lactic acidosis, as seen in this patient. Since smoking does not impact lactate metabolism, it is the least relevant factor among the given options, making it the correct answer. Explanation for the Incorrect Answers: (A) Advanced Age Elderly patients are at higher risk for metformin-associated lactic acidosis due to age-related decline in renal function, reduced hepatic metabolism, and overall decreased physiological reserve. Older individuals also have a higher likelihood of underlying kidney and liver disease, which impairs lactate clearance. (B) Liver Dysfunction The liver is responsible for lactate metabolism and gluconeogenesis. In liver dysfunction, lactate clearance is impaired, leading to accumulation of lactic acid, which can predispose to metformin-associated lactic acidosis. Conditions like cirrhosis and hepatitis increase the risk of metformin toxicity and acidosis. (C) Renal Dysfunction Renal impairment is the most critical risk factor for lactic acidosis in metformin users. Metformin is primarily excreted by the kidneys, and any decrease in renal clearance leads to drug accumulation, increasing the risk of lactic acidosis. Patients with CKD (Chronic Kidney Disease) or acute kidney injury (AKI) are particularly vulnerable to this complication.",
      "correct_choice_id": 254655,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/10143121700305984/10143121700305984.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/10143121700305984/10143121700305984.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59904,
      "choices": [
        {
          "id": 254656,
          "text": "Increases insulin secretion from the pancreas"
        },
        {
          "id": 254657,
          "text": "Decreases hepatic glucose production"
        },
        {
          "id": 254658,
          "text": "Increases intestinal glucose absorption"
        },
        {
          "id": 254659,
          "text": "Enhances peripheral insulin sensitivity"
        }
      ],
      "text": "A 45-year-old woman with type 2 diabetes is prescribed metformin. Which of the following mechanisms best explains how metformin helps lower blood glucose levels?",
      "unique_key": "Q4489486",
      "question_audio": null,
      "question_video": null,
      "map_id": 34317918,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Decreases hepatic glucose production. Metformin is a first-line drug for the treatment of type 2 diabetes mellitus (T2DM) and belongs to the biguanide class. Its primary mechanism of action is the inhibition of hepatic gluconeogenesis, meaning it reduces glucose production by the liver. It does this by activating AMP-activated protein kinase (AMPK), which decreases the expression of enzymes involved in gluconeogenesis and increases glucose uptake by peripheral tissues. Additionally, metformin reduces glycogenolysis, further lowering blood glucose levels. Unlike other antidiabetic drugs, metformin does not cause hypoglycemia because it does not increase insulin secretion. Explanation of Incorrect Options: (A) Increases insulin secretion from the pancreas – Incorrect. Unlike sulfonylureas and meglitinides, metformin does not stimulate insulin release from pancreatic beta cells. Instead, it acts mainly on the liver to decrease glucose production and improves insulin sensitivity in peripheral tissues. (C) Increases intestinal glucose absorption – Incorrect. Metformin actually does the opposite—it reduces glucose absorption in the intestine, leading to lower postprandial glucose levels. Increasing glucose absorption would worsen hyperglycemia, which is not a characteristic of metformin. (D) Enhances peripheral insulin sensitivity – Partially correct but not the primary mechanism. While metformin does enhance insulin sensitivity in skeletal muscles and adipose tissues, this effect is secondary to its main action of reducing hepatic glucose production. The primary way metformin lowers blood glucose is by decreasing gluconeogenesis in the liver.",
      "correct_choice_id": 254657,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59905,
      "choices": [
        {
          "id": 254660,
          "text": "Sulfonylureas"
        },
        {
          "id": 254661,
          "text": "DPP-4 inhibitors"
        },
        {
          "id": 254662,
          "text": "Meglitinides"
        },
        {
          "id": 254663,
          "text": "SGLT2 inhibitors"
        }
      ],
      "text": "A 40-year-old woman with insulin-dependent diabetes mellitus is concerned about hypoglycemia. Which of the following medications can help reduce the risk of hypoglycemia while improving glycemic control?",
      "unique_key": "Q6729555",
      "question_audio": null,
      "question_video": null,
      "map_id": 34446448,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) DPP-4 inhibitors. DPP-4 (Dipeptidyl Peptidase-4) inhibitors, such as sitagliptin, saxagliptin, and linagliptin, help improve glycemic control by increasing the levels of incretin hormones (GLP-1 and GIP). These hormones enhance glucose-dependent insulin secretion and suppress glucagon release, leading to better blood sugar regulation. Because DPP-4 inhibitors act in a glucose-dependent manner, they do not cause excessive insulin release when glucose levels are low, thereby reducing the risk of hypoglycemia. Additionally, these drugs have a favorable safety profile and are often used as adjunct therapy in patients with diabetes to enhance glycemic control without increasing the likelihood of low blood sugar episodes. Explanation of Incorrect Options: A. Sulfonylureas – Incorrect Sulfonylureas (e.g., glipizide, glyburide, glimepiride) work by stimulating insulin secretion from pancreatic beta cells, regardless of blood glucose levels. This continuous insulin release can lead to an increased risk of hypoglycemia, making them less suitable for patients concerned about low blood sugar episodes. C. Meglitinides – Incorrect Meglitinides (e.g., repaglinide, nateglinide) also stimulate insulin secretion but have a shorter duration of action compared to sulfonylureas. While they provide flexible dosing options around meals, they still increase the risk of hypoglycemia because they promote insulin release independently of glucose levels. D. SGLT2 inhibitors – Incorrect SGLT2 (Sodium-Glucose Cotransporter-2) inhibitors (e.g., empagliflozin, canagliflozin, dapagliflozin) lower blood sugar by preventing glucose reabsorption in the kidneys, leading to increased glucose excretion in urine. While these drugs have benefits such as weight loss and cardiovascular protection, they do not significantly reduce the risk of hypoglycemia and can sometimes lead to dehydration, urinary tract infections, or ketoacidosis.",
      "correct_choice_id": 254661,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59906,
      "choices": [
        {
          "id": 254664,
          "text": "Increases insulin sensitivity"
        },
        {
          "id": 254665,
          "text": "Promotes renal glucose excretion"
        },
        {
          "id": 254666,
          "text": "Decreases glucagon secretion"
        },
        {
          "id": 254667,
          "text": "Increases appetite"
        }
      ],
      "text": "A patient with heart failure and diabetes is prescribed canagliflozin. Which of the following effects does this medication have?",
      "unique_key": "Q8818130",
      "question_audio": null,
      "question_video": null,
      "map_id": 34301243,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Promotes renal glucose excretion. Canagliflozin is a Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor, which works by blocking glucose reabsorption in the proximal renal tubules. This mechanism leads to increased urinary glucose excretion, thereby lowering blood glucose levels independently of insulin. SGLT2 inhibitors like canagliflozin are particularly beneficial in patients with both heart failure and diabetes, as they not only improve glycemic control but also reduce cardiovascular events and hospitalization for heart failure. Additionally, these medications promote osmotic diuresis, which helps lower blood pressure and reduce fluid overload—a key benefit for heart failure patients. Explanation of Incorrect Options: A. Increases insulin sensitivity – Incorrect SGLT2 inhibitors do not directly increase insulin sensitivity. Instead, they reduce blood glucose levels by increasing glucose excretion, thereby lowering the body's overall glucose burden. While improved glucose control might lead to some secondary enhancement in insulin sensitivity, this is not the drug’s primary mechanism of action. C. Decreases glucagon secretion – Incorrect Unlike GLP-1 receptor agonists or DPP-4 inhibitors, which can reduce glucagon secretion, SGLT2 inhibitors do not significantly affect glucagon levels. In fact, some studies suggest that SGLT2 inhibitors may increase glucagon secretion in response to lower insulin levels. D. Increases appetite – Incorrect Canagliflozin and other SGLT2 inhibitors are actually associated with weight loss, not increased appetite. This occurs due to the loss of calories through glucose excretion and the mild diuretic effect, which can lead to reductions in both body weight and visceral fat.",
      "correct_choice_id": 254665,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59907,
      "choices": [
        {
          "id": 254668,
          "text": "Inhibition of glucagon release"
        },
        {
          "id": 254669,
          "text": "Stimulation of insulin secretion"
        },
        {
          "id": 254670,
          "text": "Increased water reabsorption in the kidneys"
        },
        {
          "id": 254671,
          "text": "Decreased renal blood flow"
        }
      ],
      "text": "A patient with diabetes insipidus is treated with desmopressin. What is the primary action of desmopressin in the management of this condition?",
      "unique_key": "Q3399059",
      "question_audio": null,
      "question_video": null,
      "map_id": 34441738,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Increased water reabsorption in the kidneys. Desmopressin (DDAVP) is a synthetic analog of antidiuretic hormone (ADH), also known as vasopressin. It primarily acts on the V2 receptors in the renal collecting ducts, stimulating the insertion of aquaporin-2 channels into the tubular cell membranes. This leads to increased water reabsorption, reducing excessive urine output and preventing dehydration in patients with diabetes insipidus (DI). Desmopressin is particularly effective in central diabetes insipidus, where there is a deficiency of ADH due to damage to the hypothalamus or pituitary gland. It does not work in nephrogenic DI, where the kidneys are resistant to ADH. By restoring water balance, desmopressin helps control polyuria (excessive urination) and polydipsia (excessive thirst), which are hallmark symptoms of diabetes insipidus. Explanation of Incorrect Options: A. Inhibition of glucagon release – Incorrect Desmopressin has no significant effect on glucagon secretion. Glucagon is a hormone secreted by the pancreas that increases blood glucose levels by stimulating glycogen breakdown in the liver. The regulation of glucagon is primarily influenced by glucose levels, insulin, and other metabolic factors, not by ADH or desmopressin. B. Stimulation of insulin secretion – Incorrect Insulin secretion is regulated by blood glucose levels and pancreatic beta-cell function. Desmopressin does not stimulate insulin release, nor does it play a role in glucose metabolism. It is primarily used for water balance disorders, such as diabetes insipidus and nocturnal enuresis (bedwetting). D. Decreased renal blood flow – Incorrect Desmopressin does not directly decrease renal blood flow. While vasopressin (natural ADH) can cause vasoconstriction via V1 receptors, desmopressin is highly selective for V2 receptors in the kidneys and has minimal vasoconstrictive effects. Instead of reducing renal blood flow, it helps the kidneys retain water, reducing urine output.",
      "correct_choice_id": 254670,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59908,
      "choices": [
        {
          "id": 254672,
          "text": "Acarbose"
        },
        {
          "id": 254673,
          "text": "Canagliflozin"
        },
        {
          "id": 254674,
          "text": "Metformin"
        },
        {
          "id": 254675,
          "text": "Glimipiride"
        }
      ],
      "text": "Which drug increases liver and tissue sensitivity to insulin by activating AMP-activated protein kinases which play a key role in insulin signalling?",
      "unique_key": "Q2808481",
      "question_audio": null,
      "question_video": null,
      "map_id": 34793805,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Metformin. Metformin is a biguanide and the first-line medication for the treatment of type 2 diabetes mellitus (T2DM). It works primarily by activating AMP-activated protein kinase (AMPK), which plays a crucial role in insulin signaling, glucose metabolism, and lipid regulation. Activation of AMPK leads to: Increased insulin sensitivity in the liver and peripheral tissues Reduced hepatic gluconeogenesis (decreasing glucose production by the liver) Increased glucose uptake by muscles Decreased intestinal glucose absorption Metformin is particularly effective in reducing fasting blood glucose levels and has additional benefits such as weight neutrality or mild weight loss, improvement in lipid profiles, and potential cardiovascular protection. It is widely used due to its low risk of hypoglycemia, unlike insulin secretagogues. Explanation of Incorrect Options: A. Acarbose – Incorrect Acarbose is an alpha-glucosidase inhibitor that works by delaying carbohydrate digestion and absorption in the intestines, leading to postprandial glucose control. It does not affect insulin sensitivity or activate AMPK, making it unsuitable as the correct answer. B. Canagliflozin – Incorrect Canagliflozin is an SGLT2 inhibitor, which works by blocking sodium-glucose co-transporter 2 (SGLT2) in the kidneys, promoting renal glucose excretion and reducing blood sugar levels. While it provides benefits such as weight loss and cardiovascular protection, it does not increase insulin sensitivity through AMPK activation like metformin does. D. Glimepiride – Incorrect Glimepiride is a sulfonylurea, which works by stimulating pancreatic beta cells to secrete more insulin, independent of glucose levels. This can lead to hypoglycemia and weight gain. Unlike metformin, glimepiride does not increase insulin sensitivity or activate AMPK. Instead, it increases insulin secretion, making it mechanistically different from metformin.",
      "correct_choice_id": 254674,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59909,
      "choices": [
        {
          "id": 254676,
          "text": "Metformin"
        },
        {
          "id": 254677,
          "text": "Dapagliflozin"
        },
        {
          "id": 254678,
          "text": "Semaglutide"
        },
        {
          "id": 254679,
          "text": "Sitagliptin"
        }
      ],
      "text": "A 60-year-old female patient with diabetes and cardiovascular disease is being considered for a new oral medication that acts on the gut to decrease glucose absorption and also induces weight loss. Which of the following medications fits this description?",
      "unique_key": "Q5498617",
      "question_audio": null,
      "question_video": null,
      "map_id": 34653449,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Semaglutide. Semaglutide is a GLP-1 receptor agonist that acts on the gut to decrease glucose absorption, slow gastric emptying, and reduce appetite, leading to weight loss. It enhances insulin secretion in a glucose-dependent manner while suppressing glucagon release, improving glycemic control. In addition, semaglutide has significant cardiovascular benefits, making it an excellent choice for patients with diabetes and cardiovascular disease. Its ability to promote weight loss distinguishes it from many other diabetes medications. Explanation of Incorrect Options: A. Metformin – Incorrect Metformin is a first-line drug for type 2 diabetes that primarily works by reducing hepatic glucose production and increasing insulin sensitivity in peripheral tissues. While it may cause modest weight loss, it does not significantly affect gut glucose absorption or gastric motility like semaglutide. Additionally, metformin does not have the same cardiovascular benefits seen with GLP-1 receptor agonists. B. Dapagliflozin – Incorrect Dapagliflozin is an SGLT2 inhibitor that works by promoting renal glucose excretion rather than acting on the gut. It does have cardiovascular benefits and promotes weight loss, but its mechanism differs from semaglutide. It does not directly slow gastric emptying or suppress appetite, making it an incorrect choice based on the question’s description. D. Sitagliptin – Incorrect Sitagliptin is a DPP-4 inhibitor that prolongs the action of endogenous GLP-1, leading to mild glucose control improvement. However, it does not significantly reduce weight or strongly affect gastric emptying. Unlike GLP-1 receptor agonists like semaglutide, DPP-4 inhibitors are weight-neutral and have less pronounced cardiovascular benefits.",
      "correct_choice_id": 254678,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59910,
      "choices": [
        {
          "id": 254680,
          "text": "Glimepiride"
        },
        {
          "id": 254681,
          "text": "Empagliflozin"
        },
        {
          "id": 254682,
          "text": "Metformin"
        },
        {
          "id": 254683,
          "text": "Sitagliptin"
        }
      ],
      "text": "A 55-year-old man with type 2 diabetes and a recent myocardial infarction is being considered for a new therapy that can reduce cardiovascular risk and promote weight loss. Which of the following agents would be most beneficial for this patient?",
      "unique_key": "Q4319489",
      "question_audio": null,
      "question_video": null,
      "map_id": 34869140,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Empagliflozin. Empagliflozin is an SGLT2 inhibitor that lowers blood glucose by promoting renal glucose excretion. It has been shown to reduce cardiovascular risk, particularly in patients with type 2 diabetes and a history of myocardial infarction (MI) or heart failure. It also promotes weight loss and reduces blood pressure, making it a highly beneficial choice for this patient. Clinical trials, such as the EMPA-REG OUTCOME trial, have demonstrated that empagliflozin significantly reduces cardiovascular mortality, heart failure hospitalizations, and all-cause mortality in diabetic patients with established cardiovascular disease. Explanation of Incorrect Options: A. Glimepiride – Incorrect Glimepiride is a sulfonylurea, which works by stimulating insulin secretion from pancreatic beta cells. While it is effective at lowering blood sugar, it does not provide cardiovascular benefits and is associated with weight gain and an increased risk of hypoglycemia. Given this patient’s history of MI, empagliflozin is a much better option. C. Metformin – Incorrect Metformin is a first-line treatment for type 2 diabetes due to its ability to reduce hepatic glucose production and improve insulin sensitivity. While it has some cardiovascular benefits, it is not as effective as SGLT2 inhibitors or GLP-1 receptor agonists in reducing cardiovascular events in high-risk patients. Additionally, it does not promote significant weight loss like empagliflozin. D. Sitagliptin – Incorrect Sitagliptin is a DPP-4 inhibitor that prolongs endogenous GLP-1 action, leading to improved insulin secretion and reduced glucagon release. However, it is weight-neutral and does not provide significant cardiovascular benefits like SGLT2 inhibitors. Therefore, it is not the best choice for a patient with a history of MI.",
      "correct_choice_id": 254681,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 59911,
      "choices": [
        {
          "id": 254684,
          "text": "Tirzepatide"
        },
        {
          "id": 254685,
          "text": "Semaglutide"
        },
        {
          "id": 254686,
          "text": "Dulaglutide"
        },
        {
          "id": 254687,
          "text": "Liraglutide"
        }
      ],
      "text": "A 50-year-old woman with type 2 diabetes is started on a new injectable medication that acts as a dual GIP and GLP-1 receptor agonist. What is the name of this medication?",
      "unique_key": "Q2172967",
      "question_audio": null,
      "question_video": null,
      "map_id": 34028430,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Tirzepatide. Explanation: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes weight loss. Its dual action leads to greater glucose control and weight reduction compared to GLP-1 receptor agonists alone. Tirzepatide has been shown to provide significant HbA1c reduction and cardiovascular benefits, making it a powerful option for managing type 2 diabetes and obesity. Explanation of Incorrect Options: B. Semaglutide – Incorrect Semaglutide is a GLP-1 receptor agonist, but it does not act on GIP receptors. While semaglutide is highly effective for blood sugar control and weight loss, tirzepatide’s dual GIP and GLP-1 action makes it superior in some aspects, particularly in metabolic effects. C. Dulaglutide – Incorrect Dulaglutide is also a GLP-1 receptor agonist and is used for type 2 diabetes management. However, it does not activate GIP receptors, making it less effective for weight loss and overall glucose control compared to tirzepatide. D. Liraglutide – Incorrect Liraglutide is another GLP-1 receptor agonist used for diabetes and weight management but lacks GIP receptor agonist activity. Although it promotes weight loss and cardiovascular benefits, it does not have the same dual mechanism as tirzepatide.",
      "correct_choice_id": 254684,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}